Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clostridium butyricum as adjuvant therapy after gastrectomy
ChiCTR2000040915Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Dec 2020
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gastric cancer (GC) comparing Clostridium butyricum with Control: placebo (2 arms). Primary endpoints: Blood routine, Liver function and 3 more. Started Dec 2020; status: recruiting.
02
Drugs
clostridium butyricum
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2000040915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040915.